Chahra Chbili | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Assist. Prof. Dr. Chahra Chbili | Clinical Neuroscience | Best Researcher Award

Assist. Prof. Dr. Chahra Chbili | University of Sousse | Tunisia

Dr. Chahra Chbili is an Assistant Professor of Pharmacology at the Higher School of Health Sciences and Techniques of Sousse (ESSTSS) and a member of the Research Laboratory of Metabolic Biophysics and Applied Pharmacology (LR/12ES02) at the Faculty of Medicine Ibn El Jazzar of Sousse, Tunisia. Her academic journey spans extensive training in biological sciences, genetics, and medical biotechnology, with a Ph.D. earned with highest honors for her work on the pharmacokinetic and pharmacogenetic study of carbamazepine therapy in epileptic and bipolar patients. Dr. Chbili’s research focuses on pharmacogenetics, pharmacokinetics, and the molecular mechanisms underlying drug efficacy and toxicity. She has contributed significantly to studies exploring the genetic determinants of drug metabolism, including investigations into glutathione-S-transferases in tuberculosis patients with drug-induced hepatotoxicity. Skilled in advanced laboratory techniques such as PCR, FISH, ELISA, and HPLC-MS, she has developed expertise in integrating molecular biology with clinical pharmacology. Dr. Chbili has authored 17 scientific documents, accumulated 138 citations across 123 indexed works, and maintains an h-index of 7, reflecting her impactful contributions to pharmacological and biomedical research in Tunisia and beyond.

Profiles: Scopus | Orcid | Research Gate

Featured Publications

Chbili, C., Mrad, S., Graiet, H., Selmi, M., Maatoug, J., Maoua, M., Abdellaoui, L., Mrizek, N., Nouira, M., Ben Fredj, M., et al. (2024). Randomized, placebo-controlled pilot study investigating the effects of Laurus nobilis tea on lipid profiles and oxidative stress biomarkers in healthy North African volunteers. The North African Journal of Food and Nutrition Research, 8(17), 86–98.

Chbili, C., Fathallah, N., Laadhari, C., Ouni, B., Saguem, S., Ben Fredj, M., Abdelghani, A., Ben Saad, H., & Ben Salem, C. (2022). Glutathione-S-transferase genetic polymorphism and risk of hepatotoxicity to antitubercular drugs in a North-African population: A case-control study. Gene, 808, 146019.

Rebai, A., Chbili, C., Ben Amor, S., Hassine, A., Ben Ammou, S., & Saguem, S. (2021). Effects of glutathione S-transferase M1 and T1 deletions on Parkinson’s disease risk among a North African population. Revue Neurologique, 177(1–2), 93–99.

Chbili, C. (2021, August 22). The effect of Origanum majorana tea on motor and non-motor symptoms in patients with idiopathic Parkinson’s disease: A randomized controlled pilot study. Journal article.

Chbili, C., Maoua, M., Selmi, M., Mrad, S., Khairi, H., Limem, K., Mrizek, N., Saguem, S., & Ben Fredj, M. (2020). Evaluation of daily Laurus nobilis tea consumption on lipid profile biomarkers in healthy volunteers. Journal of the American College of Nutrition, 39(6), 518–526.

Rebai, A., Reçber, T., Nemutlu, E., Chbili, C., Kurbanoglu, S., Kir, S., Ben Amor, S., Özkan, S. A., & Saguem, S. (2020). GC-MS based metabolic profiling of Parkinson’s disease with glutathione S-transferase M1 and T1 polymorphism in Tunisian patients. Combinatorial Chemistry and High Throughput Screening, 23(8), 785–794.

Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Dr. Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Dr.  Liliana Elena Weimer, Center For Global Health Istituto Superiore di Sanita’ Rome, Italy.

Dr. Liliana Elena Weimer is a highly accomplished physician and clinical researcher , where she has risen to the prestigious Level II “First Researcher” position. Her professional focus lies in clinical trials for infectious diseases, particularly HIV and Hepatitis C. She has played a critical role in major national and international research efforts, including collaborations with the U.S. Clinical Trials Group and leadership of the large-scale PITER cohort involving 25,000 HCV patients. She is known not only for her scientific contributions but also for her humanitarian efforts during the COVID-19 emergency. Among her recognitions is the 1st Prize at the 2019 International Congress on Hepatitis C in Seville. Throughout her career, she has exemplified scientific integrity, dedication, and service to public health.

Profile

Google Scholar

🎓 Early Academic Pursuits

Born on December 19, 1965, in Buenos Aires to Italian parents, Dr. Liliana Elena Weimer embraced her dual heritage and committed herself to a life in medicine and research. With Italian citizenship and deep academic determination, she laid the groundwork for her career by studying medicine, ultimately finding her professional home in Italy. Her academic path, though not fully detailed, clearly led her toward a focus on clinical medicine and infectious diseases, with her earliest professional roles marking the beginning of a lifelong engagement in public health and biomedical research. Her intellectual dedication and international roots later became an asset in global research collaborations.

🩺 Professional Endeavors

Dr. Weimer’s distinguished career spans over three decades at the Italian National Institute of Health (ISS), beginning in 1985. Starting as a dedicated clinical physician, she ascended to Level III researcher status by 1990 and continued to grow into higher ranks, culminating in her success in the national Art. 15 competition for the Level II “First Researcher” role in 2022, officially backdated to 2021. Throughout her tenure at ISS, she became a central figure within the Global Health Center in Rome. Known for her tireless commitment, she often described her career not simply as a job but as a “mission,” emphasizing both her personal and professional passion for making a difference in human health.

🧪 Contributions and Research Focus

Specializing in clinical trials, Dr. Weimer has coordinated and participated in numerous groundbreaking studies in HIV and Hepatitis C (HCV). Since the early 1990s, she has collaborated closely with renowned figures such as Prof. Giovanni Rossi, Prof. Stefano Vella, and Prof. Gianni Rezza, contributing to some of the most pivotal HIV antiretroviral therapy trials in history. Her research efforts extended to co-leading and organizing both national and international multicenter clinical trials. Notably, she has been at the forefront of the PITER study, a major nationwide cohort that follows 25,000 patients undergoing HCV treatment—one of the most comprehensive initiatives in Italy in the fight against hepatitis.

🌍 Global Collaborations and Humanitarian Engagement

Her impact extends beyond Italy, thanks to her active involvement with the U.S.-based American Clinical Trials Group on HIV studies. These collaborations have enhanced international understanding and treatment of HIV/AIDS. In addition to her clinical and research commitments, Dr. Weimer also devoted herself to frontline service during the COVID-19 pandemic. Volunteering both with the Civil Protection unit and at Bambino Gesù Children’s Hospital, she demonstrated profound humanitarian values. Her presence during a critical time underscored her belief in serving communities not just from behind a lab desk but also on the ground, directly supporting patients and health systems under strain.

🏅 Accolades and Recognition

Dr. Weimer’s work has been acknowledged at both national and international levels. One of the most prominent recognitions she received was the 1st Prize at the International Congress on Hepatitis C held in Seville in November 2019, a testament to her excellence and influence in the field of infectious disease research. Her achievements are not only measured in accolades but also in the tangible difference her work has made in advancing therapy options and clinical management of chronic viral diseases. Her rise within the ISS and the trust placed in her leadership of major research projects further affirm her standing within the scientific community.

💡 Impact and Influence

Over the course of her extensive career, Dr. Weimer has significantly shaped clinical research strategies in Italy, especially regarding chronic viral infections. Her coordination of thousands of patient cases within structured clinical trials has informed policy decisions and improved treatment protocols nationwide. Her presence at the ISS has also influenced future generations of researchers and clinicians, many of whom benefited from her mentorship, leadership, and example of scientific integrity. Through her rigorous methods and patient-focused approach, she has played a key role in Italy’s standing as a leader in global health research, especially in relation to HIV and HCV.

🔬 Legacy and Future Contributions

Looking forward, Dr. Weimer’s contributions will continue to echo through the fields of virology and clinical medicine. Her involvement in the PITER cohort and other studies has laid down essential groundwork for long-term epidemiological surveillance and patient care strategies. With her appointment as First Researcher, she enters a new chapter of leadership, likely to drive more innovative, patient-centered research initiatives in global health. Her legacy lies not only in her publications or awards but also in the thousands of lives improved by the treatments she helped to test, refine, and implement. The combination of scientific rigor and heartfelt service defines her enduring contribution to modern medicine.

Publication

  • Outcome of sustained virological responders with histologically advanced chronic hepatitis C – TR Morgan, MG Ghany, HY Kim, KK Snow, ML Shiffman, JL De Santo, … – 2010

 

  • Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‐year follow‐up of 150 patients – SL George, BR Bacon, EM Brunt, KL Mihindukulasuriya, J Hoffmann, … – 2009

 

  • Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis – V Saxena, L Nyberg, M Pauly, A Dasgupta, A Nyberg, B Piasecki, … – 2015

 

  • Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy – D Persaud, SC Ray, J Kajdas, A Ahonkhai, GK Siberry, K Ferguson, … – 2007

 

  • Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study – EB Tapper, BR Bacon, MP Curry, DT Dieterich, SL Flamm, LE Guest, … – 2016

 

  • Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with< 50 copies/ml HIV-1 RNA – S Baroncelli, CM Galluzzo, MF Pirillo, MG Mancini, LE Weimer, … – 2009

 

  • Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study – R Mellado-Artigas, LE Mujica, ML Ruiz, BL Ferreyro, F Angriman, E Arruti, … – 2021

 

  • A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients – M Floridia, R Bucciardini, D Ricciardulli, V Fragola, MF Pirillo, LE Weimer, … – 1999

 

  • Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort – LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, … – 2017

 

  • Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER network – LA Kondili, GB Gaeta, D Ieluzzi, AL Zignego, M Monti, A Gori, A Soria, … – 2017

 

🏁 Conclusion

Dr. Weimer stands as a distinguished figure in the field of global health research, with deep expertise in clinical trials and infectious diseases. Her legacy is marked by landmark contributions to HIV and HCV treatment protocols, influential collaborations, and compassionate public service. Her ongoing work continues to shape public health policy and medical research in Italy and beyond. As she advances in her leadership role at the ISS, her experience, insight, and dedication will remain vital to future innovations in clinical research and global health.

Ali Esmaeilzadeh Pilehroud | Clinical Neuroscience | Neuroscience Academic Distinction Award

Published on by Neuroscientists

Dr. Ali Esmaeilzadeh Pilehroud | Clinical Neuroscience | Neuroscience Academic Distinction Award

Dr. Ali Esmaeilzadeh,  Pilehroud Allameh Tabataba’i University, Iran.

Ali Esmaeilzadeh Pilehroud is a distinguished teacher and university professor at Allameh Tabataba’i University in Tehran, specializing in psychology with a strong focus on neuroscience and child cognition. Holding a Ph.D. and an international certificate in psychotherapy for children, he has seamlessly blended academic excellence with practical expertise. His career is marked by significant research projects, multiple influential publications, and a commitment to nurturing future psychologists. His work consistently bridges scientific innovation with educational impact, earning him recognition both nationally and internationally.

Profile

Google Scholar

 

🎓 Early Academic Pursuits

Ali Esmaeilzadeh Pilehroud began his academic journey with a profound passion for understanding the human mind. He earned his Ph.D. in Psychology from the prestigious Allameh Tabataba’i University in Tehran, where his research laid a strong foundation for his future contributions to the fields of psychology and psychotherapy. Additionally, he obtained an international certificate specializing in psychology and psychotherapy for children, reflecting his early commitment to focusing on child development and mental health.

🏛️ Professional Endeavors

Following his academic accomplishments, Ali Esmaeilzadeh Pilehroud embarked on a dual career as a teacher and a university professor at Allameh Tabataba’i University, one of Iran’s leading institutions. His role bridges both education and mentorship, allowing him to mold the minds of future psychologists. His deep involvement in both theoretical and practical aspects of psychology demonstrates his dedication to merging academic excellence with real-world application.

🧠 Contributions and Research Focus

Ali Esmaeilzadeh Pilehroud’s research primarily revolves around neuroscience and child cognition, highlighting his interest in the biological and psychological foundations of development. He has successfully completed two major research projects exploring these domains, contributing valuable insights to the scientific community. His work emphasizes understanding how early neural and cognitive development can be supported through targeted psychological interventions, particularly benefiting children’s growth and mental wellness.

📚 Books and Publications

A testament to his scholarly dedication, Ali Esmaeilzadeh Pilehroud has authored five volumes of academic and professional books, each carrying its own ISBN. These publications enrich the fields of psychology and child development, providing important resources for both students and practicing professionals. His writings are characterized by their accessibility and depth, offering readers a thorough understanding of complex psychological concepts.

🏆 Accolades and Recognition

Throughout his career, Ali Esmaeilzadeh Pilehroud has earned recognition for his contributions to academia and child psychology. His research works have been cited by peers, showcasing their influence and relevance. Additionally, his international certification in psychotherapy further underscores his standing in the global psychology community, distinguishing him as a leader in child-focused psychological practices.

🌍 Impact and Influence

Ali Esmaeilzadeh Pilehroud’s influence extends beyond the classroom and research labs. By integrating neuroscience with child psychology, he has advanced new methods for fostering cognitive development in children. His approach encourages educational reforms and therapeutic practices that are informed by scientific research, ultimately benefiting countless young lives and shaping a more scientifically informed society.

✨ Legacy and Future Contributions

Looking to the future, Ali Esmaeilzadeh Pilehroud remains committed to expanding his research and educational impact. His legacy is built upon a solid foundation of scientific inquiry, educational mentorship, and contributions to child psychotherapy. With plans to pursue further innovative projects, he aims to continue inspiring the next generation of psychologists while deepening the global understanding of child cognition and development.

Publication

  • Title: Lack of association between interleukin-10 gene promoter polymorphisms with HIV susceptibility and progression to AIDS
    Authors: A. Ramezani, E. Kalantar, A. Aghakhani, M. Banifazl, M. Foroughi, et al.
    Year: 2015

 

  • Title: Evaluation of acquired HIV drug resistance among people living with HIV who have taken antiretroviral therapy for 9–15 months in 14 triangular clinics in Iran, 2015–2016
    Authors: M. Mohraz, K. Tayeri, H. Namdari Tabar, Z. Bayat Jozani, L. Sadeghi, et al.
    Year: 2019

 

  • Title: Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIV-Positive Patients Receiving First Line Treatment in Iran
    Authors: L. Sadeghi, S. Moallemi, R.A. Tabatabai, A. Esmaeilzadeh, S. Ahsani-Nasab, et al.
    Year: 2018

 

  • Title: Enhanced immune responses against HIV-1 with Adenovector (gag and tat) prime/protein boost regimen and GM-CSF injection
    Authors: N.H. Rouzbahani, S. Bayanolhagh, M. Gholami, A. Esmaeilzadeh, Z.B. Jozani, et al.
    Year: 2016

 

  • Title: Comparing Theory of Mind and Executive Functions in Obsessive Compulsive Disorder, Schizophrenia, and Normal Individuals
    Authors: نیکجو وکیل آباد, اسمعیل زاده پیله رود (Nikjoo Vakilabad, Esmaeilzadeh Pilerood)
    Year: (Not clear—year not given, but possibly recent.)

 

🖋️ Conclusion

Through a lifelong dedication to psychology, research, and teaching, Ali Esmaeilzadeh Pilehroud has made lasting contributions to child development studies and cognitive neuroscience. His legacy is not only evident in his scholarly books and research projects but also in the lives of the students and professionals he has mentored. Looking ahead, he continues to inspire and innovate, shaping the future of psychological science and fostering better mental health outcomes for children worldwide.

CARMINA MONTOLIU | Clinical Neuroscience | Best Researcher Award

Published on by Neuroscientists

Prof. Dr. CARMINA MONTOLIU | Clinical Neuroscience | Best Researcher Award

Prof. Dr.  CARMINA MONTOLIU, UNIVERSIDAD DE VALENCIA/INCLIVA,  Spain.

Carmina Montoliu Felix, a Valencia-born scientist and educator, is a distinguished Catedrática de Universidad at the Universidad de Valencia, specializing in Cellular Biology and Pathology. With a strong foundation in biomedical sciences and a dual role in both academia and clinical research through INCLIVA, she has become a key figure in translational medicine in Spain. Her work focuses on uncovering cellular mechanisms of disease, supported by national recognition such as her Group A classification by ISCIII. With extensive contributions indexed on platforms like ORCID and Scopus, she has gained international visibility and continues to influence the fields of pathology and biomedicine.

Profile

Orcid

 

🎓 Early Academic Pursuits

Carmina Montoliu Felix was born in Valencia, where she also pursued her academic career rooted in the life sciences. Her early interest in biology and medical sciences led her through a rigorous academic pathway that would eventually shape her into a leading figure in cellular pathology. With a profound dedication to understanding human disease at the cellular level, she cultivated a strong foundation in biology, which became the cornerstone of her future specialization in Cellular Biology and Pathology. These formative years instilled in her a passion for translational research, which continues to drive her work.

🏛️ Professional Endeavors

Currently serving as a Catedrática de Universidad at the Facultad de Medicina y Odontología of the Universidad de Valencia, Carmina Montoliu Felix holds a prestigious position within the Departamento de Patología, specifically in the Unidad de Biología. She achieved this distinguished academic rank on November 3, 2023, under BOE nº 274, a recognition of her academic excellence and contributions to higher education. Alongside her academic post, she is also an investigadora adscrita at the Fundación INCLIVA, playing a dual role in both teaching and active biomedical research. Her employment reflects the seamless integration between university instruction and clinical research aimed at improving patient outcomes.

🧬 Contributions and Research Focus

Carmina Montoliu Felix has been a pivotal contributor to the field of Cellular Biology, with specific expertise in Pathology (Área 661). Since February 29, 2012, she has been classified as a Group A Researcher within the Instituto de Salud Carlos III (ISCIII) framework. Her research activities are aligned with the Programa de Estabilización de Investigadores and the Sistema Nacional de Salud (I3SNS), focusing on intensifying biomedical research and fostering translational discoveries. Her scientific work is characterized by its interdisciplinary nature and commitment to uncovering the molecular basis of diseases, contributing significantly to both national and international health research landscapes.

🏅 Accolades and Recognition

Dr. Montoliu Felix’s academic excellence has been affirmed through numerous accolades, including the Group A classification by the Comisión Técnica de Evaluación de Recursos Humanos del ISCIII, one of the highest distinctions for biomedical researchers in Spain. Her appointment as a full professor is a testament to her leadership in medical education and scientific research. She is widely recognized among her peers for her scholarly impact, rigor, and commitment to nurturing future scientists and medical professionals.

🌍 Impact and Influence

Her work not only resonates within academic circles but also extends into clinical research through her active role at INCLIVA. By integrating research and practice, Carmina Montoliu Felix exemplifies how scientific inquiry can lead to tangible health benefits. Her influence spans collaborations with national healthcare systems and academic institutions, reinforcing her role as a key figure in the biomedical field. Through platforms such as ORCID and Scopus (ORCID ID: 0000-0002-4740-4788; Scopus ID: 6701923138), her contributions are accessible globally, further amplifying her scientific impact.

🔬 Legacy and Future Contributions

With a career marked by consistent advancement and dedication to discovery, Carmina Montoliu Felix is poised to continue shaping the future of cellular pathology and biomedical research in Spain and beyond. Her dual engagement in academia and clinical research ensures that her legacy will include both scientific breakthroughs and a generation of inspired students and researchers. Looking ahead, she is expected to further expand the integration of molecular biology into clinical diagnostics, ultimately improving patient care through science.

📚 A Life Committed to Science and Society

Beyond her technical expertise and professional roles, Carmina Montoliu Felix embodies the ideals of a scholar deeply committed to the betterment of society through science. Her residence and professional base in Valencia, her continuous academic contributions, and her service within public institutions paint the portrait of a researcher who bridges the lab and the community. Through her enduring efforts, she not only advances knowledge but also enhances the collective understanding of human health and disease.

Publication

  • Title: Valproate Damaging Effect on Erythrocyte Metabolism as a Decisive Factor in the Development of Encephalopathy
    Authors: Lyudmila Tikhonova; Eugene Maevsky; Carmina Montoliu; Elena Kosenko
    Year: 2025

 

  • Title: Ammoniagenic Action of Valproate without Signs of Hepatic Dysfunction in Rats: Possible Causes and Supporting Evidence
    Authors: Gubidat Alilova; Lyudmila Tikhonova; Carmina Montoliu; Elena Kosenko
    Year: 2024

 

  • Title: Automatic Video-Oculography System for Detection of Minimal Hepatic Encephalopathy Using Machine Learning Tools
    Authors: Alberto Calvo Córdoba; Cecilia Elisabet García Cena; Carmina Montoliu
    Year: 2023

 

  • Title: Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients
    Authors: Alessandra Fiorillo; Juan José Gallego Roig; Franc Casanova; Amparo Urios; MP Ballester; Teresa San-Miguel; Javier Megías Vericat; Elena Kosenko; Tosca J; Maria-Pilar Rios et al.
    Year: 2023

 

  • Title: Mild Cognitive Impairment Is Associated with Enhanced Activation of Th17 Lymphocytes in Non-Alcoholic Fatty Liver Disease
    Authors: Alessandra Fiorillo; Juan José Gallego Roig; Franc Casanova; Carla Giménez-Garzó; Amparo Urios; MP Ballester; Lucia Durbán; Maria-Pilar Rios; Javier Megías Vericat; Teresa San-Miguel et al.
    Year: 2023

 

  • Title: Erythrocytes Functionality in SARS-CoV-2 Infection: Potential Link with Alzheimer’s Disease
    Authors: Elena Kosenko; Lyudmila Tikhonova; Gubidat Alilova; Carmina Montoliu
    Year: 2023

 

  • Title: Plasma Extracellular Vesicles Play a Role in Immune System Modulation in Minimal Hepatic Encephalopathy
    Authors: Juan José Gallego; Alessandra Fiorillo; Franc Casanova-Ferrer; Amparo Urios; MP Ballester; Lucia Durbán; Javier Megías; Teresa Rubio; Andrea Cabrera-Pastor; Desamparados Escudero-García et al.
    Year: 2022

 

  • Title: Matched Paired Primary and Recurrent Meningiomas Points to Cell-Death Program Contributions to Genomic and Epigenomic Instability along Tumor Progression
    Authors: Teresa San-Miguel; Javier Megías; Daniel Monleon; Lara Navarro Cerveró; Lisandra Muñoz; Carmina Montoliu; Marina Meri; Pedro Roldán; Miguel Cerdá-Nicolás; Concha López-Ginés
    Year: 2022

 

  • Title: Is NMDA-Receptor-Mediated Oxidative Stress in Mitochondria of Peripheral Tissues the Essential Factor in the Pathogenesis of Hepatic Encephalopathy?
    Authors: Elena Kosenko; Lyudmila Tikhonova; Gubidat Alilova; Carmina Montoliu
    Year: 2022

 

  • Title: A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease
    Authors: Carla Giménez-Garzó; Alessandra Fiorillo; MP Ballester; Juan José Gallego Roig; Franc Casanova-Ferrer; Amparo Urios; Salvador Benlloch; Marti-Aguado D; Teresa San-Miguel; Tosca J et al.
    Year: 2021

 

✅ Conclusion

Carmina Montoliu Felix’s career reflects a rare blend of scientific rigor, academic leadership, and social impact. Her journey from student to full professor showcases her dedication to advancing both knowledge and healthcare. As she continues to lead research at the intersection of cellular biology and clinical application, her legacy will not only be measured in published studies and prestigious titles, but also in the real-world health outcomes and inspired minds her work cultivates. Her future contributions promise to deepen our understanding of disease and strengthen the bridge between science and society.

 

Camilla Bellone | Translational Neuroscience | Best Researcher Award

Published on by Neuroscientists

Assoc. Prof. Dr. Camilla Bellone | Translational Neuroscience | Best Researcher Award

Assoc. Prof. Dr. Camilla Bellone,  University of Geneva, Switzerland.

Dr. Camilla Bellone is a renowned neuroscientist whose academic and research career has been marked by excellence, innovation, and impact. From her foundational training in Italy to her leadership role in Geneva, she has made pioneering contributions to understanding the neural underpinnings of social behavior. Her work bridges basic science and clinical relevance, and she has played a vital role in training, mentorship, and international collaboration within the neuroscience community.

Profile

Google Scholar

 

🎓 Early Academic Pursuits

Dr. Camilla Bellone began her academic journey with a Master’s degree in Pharmacy from the University of Milano in 2000. With a strong foundation in pharmacology and medical chemistry, she pursued her Ph.D. in “Pharmacology, Toxicology, and Medical Chemotherapy” at the same institution, completing it in 2006. Her early education shaped a robust scientific mindset, preparing her for a career at the intersection of neuroscience and pharmacology. These formative years set the tone for her later work on the molecular mechanisms that govern complex behaviors in both healthy and diseased states.

🧪 Professional Endeavors

After her doctoral studies, Dr. Bellone enhanced her research acumen through a postdoctoral fellowship at the University of California, San Francisco (UCSF), gaining international exposure. She later returned to Switzerland, where she served as a scientist under the Ambizione Fellowship at the University of Geneva. Her academic path took a significant leap when she became an Assistant Professor at the University of Lausanne in 2014, followed by a transition to the University of Geneva in 2016. In 2020, she was promoted to Associate Professor in the Department of Basic Neuroscience, where she continues to lead cutting-edge investigations and mentor future neuroscientists.

🧠 Contributions and Research Focus

At the core of Dr. Bellone’s research lies a deep interest in the neurobiological basis of social behavior, with a particular focus on how these processes are disrupted in neuropsychiatric disorders. Her lab explores the synaptic and circuit-level mechanisms that underpin social cognition, often using advanced molecular and behavioral techniques. Her work has provided critical insights into how alterations in neural plasticity and connectivity contribute to diseases such as schizophrenia and autism spectrum disorders. With over 40 peer-reviewed publications in high-impact journals like Nature Neuroscience and Neuron, Dr. Bellone’s research continues to advance the field of behavioral neuroscience.

🏆 Accolades and Recognition

Dr. Bellone’s scientific excellence has been recognized through several prestigious honors. In 2023, she received the EBBS Mid-Career Award and the Leenaards Scientific Prize for her collaborative project on cerebellar stimulation in schizophrenia. Earlier, she was elected to the distinguished FENS-KAVLI Network of Excellence in 2015, highlighting her position among Europe’s most promising neuroscientists. In 2014, she was honored with the Fondation du Prix Pfizer de la Recherche, marking an early milestone in her independent research career.

🌍 Impact and Influence

Beyond her lab, Dr. Bellone has made meaningful contributions to the academic and scientific community. She has delivered over 20 invited lectures at international conferences and institutions, sharing her discoveries with a global audience. As a dedicated mentor, she has guided eight master’s students and seven PhD candidates, nurturing the next generation of neuroscientists. Her commitment extends to active service on academic committees, grant review panels, and editorial boards, reflecting her role as a respected leader in the field.

👩‍🔬 Balancing Science and Life

A champion of work-life integration, Dr. Bellone has managed to thrive professionally while embracing motherhood. She took two career breaks following the birth of her three children, exemplifying resilience and balance in a demanding academic landscape. Her story is an inspiration to young scientists, especially women, striving to build careers in STEM while honoring personal life choices.

🔬 Legacy and Future Contributions

Looking ahead, Dr. Bellone’s work holds promise for transforming our understanding of social dysfunction in mental illness. Her innovative approaches—blending circuit neuroscience, pharmacology, and behavior—position her as a leading voice in the neurobiology of social behavior. With continued support from initiatives like the ERC Consolidator Grant, her research will likely pave the way for novel therapeutic interventions, leaving a lasting legacy in neuroscience and psychiatry.

Publication

  • Title: NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
    Author: P Paoletti, C Bellone, Q Zhou
    Year: 2013

 

  • Title: Cocaine triggered AMPA receptor redistribution is reversed in vivo by mGluR-dependent long-term depression
    Author: C Bellone, C Lüscher
    Year: 2006

 

  • Title: Rapid bidirectional switching of synaptic NMDA receptors
    Author: C Bellone, RA Nicoll
    Year: 2007

 

  • Title: Cocaine inverts rules for synaptic plasticity of glutamate transmission in the ventral tegmental area
    Author: M Mameli, C Bellone, MTC Brown, C Lüscher
    Year: 2011

 

  • Title: In vivo reprogramming of circuit connectivity in postmitotic neocortical neurons
    Author: A De la Rossa, C Bellone, B Golding, I Vitali, J Moss, N Toni, C Lüscher, …
    Year: 2013

 

  • Title: Mechanisms of synaptic depression triggered by metabotropic glutamate receptors
    Author: C Bellone, C Lüscher, M Mameli
    Year: 2008

 

  • Title: Effects of streptozotocin‐diabetes on the hippocampal NMDA receptor complex in rats
    Author: F Gardoni, A Kamal, C Bellone, GJ Biessels, GMJ Ramakers, F Cattabeni, …
    Year: 2002

 

  • Title: Neurons under T cell attack coordinate phagocyte-mediated synaptic stripping
    Author: G Di Liberto, S Pantelyushin, M Kreutzfeldt, N Page, S Musardo, R Coras, …
    Year: 2018

 

  • Title: mGluRs induce a long‐term depression in the ventral tegmental area that involves a switch of the subunit composition of AMPA receptors
    Author: C Bellone, C Lüscher
    Year: 2005

 

  • Title: SHANK3 controls maturation of social reward circuits in the VTA
    Author: S Bariselli, S Tzanoulinou, C Glangetas, C Prévost-Solié, L Pucci, …
    Year: 2016

 

✅ Conclusion

Dr. Bellone’s journey reflects a remarkable blend of scientific curiosity, academic leadership, and personal resilience. As she continues to explore the brain’s most intricate social circuits, her influence will undoubtedly expand across neuroscience, psychiatry, and therapeutic innovation. Her career serves as both a roadmap and an inspiration for emerging scientists navigating the evolving landscape of brain research.